dc.contributor.author | Smrke, A | |
dc.contributor.author | Thway, K | |
dc.contributor.author | H Huang, P | |
dc.contributor.author | Jones, RL | |
dc.contributor.author | Hayes, AJ | |
dc.date.accessioned | 2021-11-25T14:45:30Z | |
dc.date.available | 2021-11-25T14:45:30Z | |
dc.date.issued | 2021-09-01 | |
dc.identifier.citation | Future oncology (London, England), 2021, 17 (27), pp. 3627 - 3636 | |
dc.identifier.issn | 1479-6694 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4902 | |
dc.identifier.eissn | 1744-8301 | |
dc.identifier.doi | 10.2217/fon-2021-0030 | |
dc.description.abstract | Solitary fibrous tumor (SFT) is a rare soft tissue sarcoma subtype which mainly affects adults in the fifth and sixth decades of life. Originally part of a spectrum of tumors called hemangiopericytomas, classification has been refined such that SFTs now represent a distinct subtype. The identification of NAB2-STAT6 fusion in virtually all SFTs has further aided to define this rare subgroup. SFTs have a spectrum of behavior from benign to malignant, with evidence suggesting risk of metastases related to age at diagnosis, extent of necrosis, mitotic rate and tumor size. The standard treatment for localized disease is surgical excision with or without radiotherapy. Retrospective and prospective evidence suggests antiangiogenic treatment is effective for unresectable disease. Further translational work is required to understand the biology driving the differential behavior and identify more effective treatments for patients with metastatic disease. | |
dc.format | Print-Electronic | |
dc.format.extent | 3627 - 3636 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | FUTURE MEDICINE LTD | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Solitary fibrous tumor: molecular hallmarks and treatment for a rare sarcoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-04-30 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.2217/fon-2021-0030 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Future oncology (London, England) | |
pubs.issue | 27 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Sarcoma and Melanoma Surgery | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 17 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | |
icr.researchteam | Molecular and Systems Oncology | |
icr.researchteam | Sarcoma and Melanoma Surgery | |
dc.contributor.icrauthor | Huang, Paul | |
dc.contributor.icrauthor | Jones, Robin | |
dc.contributor.icrauthor | Hayes, Andrew | |